Belite Bio (BLTE) announced that it has commenced an underwritten public offering of American Depositary shares, or ADSs, each representing one of its ordinary shares. All of the securities in the offering are to be sold by Belite Bio. Belite Bio intends to use the net proceeds of the offering for (i) commercialization preparation, including building our in-house commercialization team, establishing sales network and systems, and preparing for the commercial manufacture of our future products, if approved, (ii) development and expansion of pipelines, and (iii) working capital and other general corporate purposes. Morgan Stanley & Co., Leerink Partners, BofA Securities and Cantor are acting as joint active book-running managers for the offering.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Positive Outlook for Belite Bio: Promising Phase 3 Results and Increased Approval Probability for Tinlarebant
- Belite Bio price target raised to $185 from $98 at H.C. Wainwright
- Belite Bio Stock (BLTE) Jumps on Positive Phase 3 STGD1 Trial Data
- Belite Bio Reports Breakthrough Phase 3 Results for Stargardt Disease Treatment